HONG KONG – Tessa Therapeutics Pte. Ltd. stumbled upon a biomarker, which it contended could make a huge difference in predicting patient reaction to treatment and survival rates. Tessa's Chief Scientific Officer John Connolly said, "The biomarker can reveal how a patient responds to cancer treatment and it can be used to predict the patient's survival rate. It works based on the protein signature from myeloid-derived suppressor cells [MDSC]."